Last reviewed · How we verify
NCT06361784: LM
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
trial in Locally Advanced Lung Non-Small Cell Carcinoma in 150 participants. Currently enrolling.
29 March 2029
Quick facts
| Lead sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 29 March 2024 |
| Primary completion | 29 March 2029 |
| Estimated completion | 29 March 2029 |
| Sites | 1 location across Italy |
Conditions studied
- Locally Advanced Lung Non-Small Cell Carcinoma — all drugs for Locally Advanced Lung Non-Small Cell Carcinoma →
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →
Who can join
Eligibility, any sex, with Locally Advanced Lung Non-Small Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy. Patients enrolled in the study will complete a set of extensive measures at the baseline, end of RT, and 9 months after treatment. Ultrasound exams, CT scans, pulmonary tests and wearable devices will assess functional and morphological parameters and the association with their variation and the dose delivered to the heart substructures and to the normal lung.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Radiation-induced cardiac substructure damage and dose constraints: a review.
Li X, Wu Y, Wang Q, Li B, et al · · 2025 · cited 3× · PMID 40474260 · DOI 10.1186/s13014-025-02668-x
Verify or expand the search:
- PubMed search for NCT06361784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Lung Non-Small Cell Carcinoma
Currently open trials in the same condition.
- NCT07012031 — Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell · Phase 1, PHASE2 · recruiting
- NCT05624996 — Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C · Phase 3 · recruiting
- NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT05166616 — Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer · Phase 1 · active not recruiting
- NCT05136846 — Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer · Phase 1 · recruiting
Other Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials
Trials by the same sponsor.
- NCT06799624 — Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr · not yet recruiting
- NCT07253402 — Microbiota-guided Radiotherapy for Head and Neck Cancer · recruiting
- NCT06938724 — Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT06999824 — Revisiting the Concept of Nerve Sparing Radical Hysterectomy · not yet recruiting
- NCT06986486 — Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06361784 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Last refreshed: 15 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06361784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing